Ninety One North America’s Alexion Pharmaceuticals ALXN Stock Holding History

Ninety One North America’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-36,520	Closed	-$4.1M	–	108
2020 Q2	$4.1M	Sell	36,520 -179,385	-83%	-$19M	0.43%	50
2020 Q1	$19.4M	Buy	215,905 +4,153	+2%	+$408K	1.61%	21
2019 Q4	$22.9M	Sell	211,752 -11,249	-5%	-$1.2M	1.87%	23
2019 Q3	$21.8M	Buy	223,001 +53,717	+32%	+$6.05M	1.97%	26
2019 Q2	$22.2M	Buy	169,284 +19,129	+13%	+$2.47M	1.95%	23
2019 Q1	$20.3M	Sell	150,155 -15,909	-10%	-$1.98M	1.92%	20
2018 Q4	$16.2M	Buy	166,064 +16,611	+11%	+$1.96M	1.72%	27
2018 Q3	$20.8M	Buy	149,453 +116,065	+348%	+$14.6M	1.78%	31
2018 Q2	$4.14M	Buy	33,388 +2,081	+7%	+$243K	0.3%	71
2018 Q1	$3.49M	Buy	31,307 +19,771	+171%	+$2.36M	0.27%	74
2017 Q4	$1.38M	Buy	+11,536	New	+$1.4M	0.22%	64

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ninety One North America's ALXN Position: Q3 2020 in Review

Ninety One North America sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 36,520 shares — an estimated $4.1M sold.

Ninety One North America first reported a position in ALXN in Q4 2017 and held it in 11 quarters. The position peaked at $22.9M in Q4 2019. 708 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Ninety One North America reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Ninety One North America sold 36,520 Alexion Pharmaceuticals shares in Q3 2020, an estimated $4.1M.
Ninety One North America first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 11 quarters.
Ninety One North America's Alexion Pharmaceuticals position peaked at $22.9M in Q4 2019.
708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Ninety One North America's 13F filing for Q3 2020, filed 12 Nov 2020.